PRTODAY / NewswireToday Free press release distribution service network

More news: Health/Surgery
Written by / Agency / Source: MDxHealth, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

MDxHealth's ConfirmMDx Genes Identify Aggressive Prostate Cancer - Data Presented at the 2014 ASCO Genitourinary Cancers Symposium -
MDxHealth's ConfirmMDx Genes Identify Aggressive Prostate Cancer


NewswireToday - /newswire/ - Irvine, CA, United States, 2014/02/03 - Data Presented at the 2014 ASCO Genitourinary Cancers Symposium - NYSE Euronext: MDXH

Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced positive results from an important study designed to identify patients with aggressive prostate cancer (PCa). The study, presented at the 2014 ASCO Genitourinary Cancers Symposium in San Francisco, USA (January 30 - February 1, 2014), confirmed that epigenetic profiling of selected genes provides prognostic information, corresponding to Gleason score (GS), that could help to identify patients with aggressive PCa.

"One of the most significant challenges in managing newly diagnosed prostate cancer patients is choosing the best treatment plan. Men diagnosed with GS6 cancer, may be eligible for active surveillance. However, today's standard 12-core TRUS-guided (transrectal ultrasound) biopsies are susceptible to under-sampling, leaving men at risk for undetected aggressive disease," noted E. David Crawford, Professor of Surgery, Professor of Radiation Oncology, and Head of the Section of Urologic Oncology at the University of Colorado Denver School of Medicine. "These promising data demonstrate that epigenetic testing is not only valuable for the decision on repeat biopsy, but may also yield important prognostic information that could help us to identify men who are at risk for aggressive disease."

In this study, the prognostic value of the epigenetic status of five genes (GSTP1, APC, RASSF1, RARB and LGALS3) in 84 prostatectomy samples with different GS's was evaluated. The results of a hierarchical clustering analysis showed that low gene methylation levels were detected in the vast majority of patient samples with GS6 and GS7 (3+4) PCa. In contrast, respectively 81% and 91% of the GS7 (4+3) and GS superior or egual 8 samples fell into the category with intermediate to high methylation levels. These data provide evidence of the potential prognostic value of epigenetically profiling selected genes to identify men with a low versus high risk for aggressive PCa.

"These important study results support our overall strategy of leveraging epigenetics to improve the diagnosis and treatment of prostate cancer patients. We were pleased to see that the data generated with the ConfirmMDx for Prostate Cancer genes, suggest the potential for prognostic utility," explained Dr. Jan Groen, CEO of MDxHealth. "With this information, we are in a position to explore expansion of the ConfirmMDx indication for use in men diagnosed with GS6 prostate cancer, which may help urologists make more informed treatment decisions."

About ConfirmMDx® for Prostate Cancer
Over 975,000 American men are diagnosed with a negative prostate biopsy each year; however approximately 25-35% of those men receive false-negative results. Under the current standard of care, prostate biopsy procedures consisting of 10-12 needle biopsy cores only sample approximately 1% of a man's prostate. This approach leaves men at risk of occult cancer, leading to a high rate of repeat biopsies, often on cancer-free men. There is an unmet medical need for a clinically effective diagnostic test to address this dilemma. ConfirmMDx for Prostate Cancer is able to detect an epigenetic field effect or 'halo' associated with the cancerization process at the DNA level. This "halo" around a cancer lesion can be present despite cells having a normal appearance under the microscope. Thus ConfirmMDx for Prostate Cancer aids urologists in identifying truly negative men who may forego an unnecessary repeat biopsy procedure.

About MDxHealth®
MDxHealth ( is a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment. The company's tests are based on proprietary gene methylation (epigenetics) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy.

For more information:
Mike Sinclair, Halsin Partners
UK: +44(0)20 7318 2955 / C: +44(0)79 6802 2075
E: msinclair[.]

Matt Clawson, Allen & Caron, Inc
US: +1 949-474-4300 - E: matt[.]

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

Your Banner Ad Here instead - Showing along with ALL Articles covering Health/Surgery Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: MDxHealth, Inc.


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #
  Your Banner Ad showing on ALL
Health/Surgery articles,
CATCH Visitors via Your Competitors Announcements!

MDxHealth's ConfirmMDx Genes Identify Aggressive Prostate Cancer

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

MDxHealth, Inc. | ConfirmMDx®
Publisher Contact: Dr. Jan Groen - 
949-812-6979 / +32 4 364 20 70 info[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any MDxHealth, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Health/Surgery via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From MDxHealth, Inc. / Company Profile

Read Health/Surgery Most Recent Related Newswires:

Stress Light Therapy Launches Crowd-Funded Campaign on
The Float Space - Brisbane's First Float and Cryo Therapy Centre to Open This November
Thought Leaders Across the Healthcare Spectrum to Participate in Industry-Wide Survey
Frost & Sullivan Names Optum 2016 North America Company of the Year for Population Health Management
R-Pharm Produces Biological Drugs in Yaroslavl with GE Healthcare's FlexFactory™ Manufacturing Platform
GE to Invest €150 Million in Biopharmaceutical Manufacturing Campus in Cork, Ireland, and Establish Advanced Manufacturing Training Centre At NIBRT
Moriarty Physical Therapy of the Hudson Valley Expands with New Office in Lagrange, NY
Ultimate Medical Group Announces A New Regenerative Medicine Division
Dr. Amir Hanna Introduces New Medical Innovation Taking the Pain Out of Physical Therapy
Samitivej Children’s Hospital Transforms its Sukhumvit Campus
Apollo eDoc Launched Online Appointment Platform
Digital Health and Point of Care Driving Growth Opportunities in the Rise of Mobile Molecular Diagnostics Says Frost & Sullivan
New Veterinarian Joins DPC Veterinary Hospital in Davie
Aggressive Expansion and Consolidation Strategies Define APAC’s Top Fifty Healthcare Services Companies Finds Frost & Sullivan
Frost & Sullivan Lauds VitreosHealth’s Advanced Predictive Analytics Solution for Providing Accurate Predictive Risk Analyses of a Population’s Health

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business



Visit  Demyk Lightmod Products, Inc.

  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (